Dr. Reddy's Halts Generic Ozempic Due to API Issue

Dr. Reddy's Laboratories has announced a delay in the commercial production of its generic semaglutide drug, commonly known as Ozempic. The company has identified an unspecified issue with the active pharmaceutical ingredient (API) in certain batches of semaglutide. This quality concern has necessitated a pause in production, impacting the planned launch of the generic medication.

The exact nature of the problem found with the active pharmaceutical ingredient has not been disclosed by the company. This development means that the market availability of Dr. Reddy's generic version of Ozempic will be postponed until the issue is resolved and production can resume safely and effectively. The company has not provided a revised timeline for the drug's release.